Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
北海康成-B:2023 年報
Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials
Canbridge Pharmaceuticals (HKG:1228) announced that it would discontinue the development of its new glioblastoma multiforme drug CAN008 after Phase II clinical trials, according to a Monday filing on
Beihai Kangcheng-B (01228.HK) decided to discontinue development and further testing of CAN008 in the field of glioblastoma
Beihai Kangcheng-B (01228.HK) announced that according to top-line data from the CAN008 phase II clinical trial for newly diagnosed glioblastoma patients, CAN008 provided no additional benefit compared to placebo in terms of progression-free survival or overall survival in patients receiving standard treatment with temozolomide and radiotherapy.
Beihai Kangcheng-B (01228.HK) grants 2.7 million share options and 2.7 million restricted share units
Beihai Kangcheng-B (01228.HK) announced that on April 9, 2024, the company granted a total of 2.7 million share purchase rights to two share option grantees under the initial public offering after-sales share option plan and a total of 2.7 million restricted share units to two restricted share unit grantees under the initial public offering post-sale restricted share unit plan.
Beihai Kangcheng-B (01228) announced annual results. Shareholders' losses amounted to 379 million yuan, a year-on-year decrease of 21.64%
Beihai Kangcheng-B (01228) announced results for the year ended December 31, 2023, with revenue of 103 million...
CANBRIDGE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Beihai Kangcheng-B (01228.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 18 | Beihai Kangcheng-B (01228.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve (among other things) the results and announcements of the company and its subsidiaries for the year ended December 31, 2023.
CANBRIDGE-B: DATE OF BOARD MEETING
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares
CANbridge Pharmaceuticals (HKG:1228) granted 10,115,000 share options to 27 participants of its post-IPO share option scheme and 3,636,000 restricted share units to 19 participants on Wednesday, a Thu
Beihai Kangcheng-B (01228) granted a total of 1.115 million share options
Beihai Kangcheng-B (01228) issued an announcement. On February 7, 2024, the company purchased after sales in accordance with the initial public development...
Beihai Kangcheng-B (01228.HK) grants share options and restricted share units
Gelonghui, Feb. 8, 丨 Beihai Kangcheng-B (01228.HK) announced that on February 7, 2024, the company granted a total of 1.115 million share purchase rights to 27 share purchase rights under the initial public offering after-sales share option plan and granted a total of 3.636 million restricted share units to 19 restricted share unit grantees under the post-initial public offering restricted share unit plan.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
RA Capital Healthcare Fund, L.P. OTC sold Beihai Kangcheng-B (01228.HK) 491,1151,000 common shares worth approximately HK$4.174,800
On December 20, according to documents disclosed by the Hong Kong Stock Exchange on December 20, RA Capital Healthcare Fund, L.P., sold $4,9151,000 common stock shares worth about HK$4.174,800 on December 19 at an average price of HK$0.085 per share. After the sale, the latest number of shares held by RA Capital Healthcare Fund, L.P., was 0 shares, and the good position ratio fell from 11.56% to 0.00%. This deal
Peter Kolchinsky sold Beihai Kangcheng-B (01228.HK) 62.1656 million common shares, worth approximately HK$5.2841 million, worth approximately HK$5.2841 million
According to reports on December 20, according to documents disclosed by the Hong Kong Stock Exchange on December 20, Peter Kolchinsky sold $Beihai Kangcheng-B (01228.HK) $62.1656 million of common stock shares worth about HK$5.284,100 on December 19 at an average price of HK$0.085 per share. After the sale, the latest number of shares held by Peter Kolchinsky was 0 shares, and the good position ratio fell from 14.64% to 0.00%. This transaction involves other related parties: Anna Inge Leonore Haas K
No Data